Results 241 to 250 of about 1,501,016 (387)

Pharmacokinetics and pharmacodynamics of empagliflozin in paediatric patients aged 10–17 years with type 2 diabetes mellitus

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims To characterize the pharmacokinetics (PK) and PK/pharmacodynamics (PD) regarding glycosylated haemoglobin (HbA1c) lowering using the paediatric data from DINAMO and to assess differences compared with adults. Methods Population PK and PK/PD models previously developed for empagliflozin in adults and adolescents were re‐estimated in a Bayesian ...
Juliane Rascher   +7 more
wiley   +1 more source

Chronic adjunctive trimazosin vasodilator therapy in heart failure: A six month double-blind placebo controlled randomized trial [PDF]

open access: green, 1982
Philip C. Kirlin   +5 more
openalex   +1 more source

Expert insight into the education of healthcare professionals on medication adherence

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Medication non‐adherence is a global health problem affecting patients with numerous medical conditions. Training healthcare professionals (HCPs) on managing the challenging issue of medication non‐adherence requires an evidence‐based approach.
Fatima Rezae   +3 more
wiley   +1 more source

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis

open access: yesNew England Journal of Medicine, 2017
P. Mease   +11 more
semanticscholar   +1 more source

Current evidence and insights on single vs. double dose of basiliximab in adult solid organ transplant recipients: A systematic review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this systematic review was to assess all available clinical data regarding the use of a single dose of basiliximab in solid organ transplantation compared to the standard double dosage, with particular interest in efficacy, safety and cost‐savings.
Alessio Provenzani   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy